Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review.
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review.
复制标题
抑郁和焦虑中的内源性大麻素系统和外源性大麻素：综述。
DOI：
10.3390/brainsci13020325
复制
发表时间：
2023-02-14
期刊：
影响因子：
3.3
通讯作者：
George, Susan R. R.
中科院分区：
文献类型：
--
作者：
Hasbi, Ahmed;Madras, Bertha K. K.;George, Susan R. R.
背景：用于医疗和娱乐用途的大麻制剂日益自由化。在多种情况下，焦虑和抑郁被认为是使用大麻素的主要原因或次要原因。目的：本综述的目的是探讨抑郁或焦虑与内源性内源性大麻素系统（ECS）失调之间的关系，以及植物大麻素和合成大麻素在治疗抑郁/焦虑症状中的用途。在简要描述大麻、大麻素受体和内源性大麻素系统的成分后，提出了大麻素参与人类抑郁和焦虑以及抑郁和焦虑动物模型的抑郁和焦虑的最重要证据。最后，提出了临床使用大麻素治疗抑郁和焦虑的证据。结论：尽管人们普遍认为大麻素（包括大麻）及其主要研究成分——四氢大麻酚（THC）和大麻二酚（CBD）——或其他合成衍生物对某些精神健康状况具有治疗作用，但我们报告的所有最近的系统评价都得出结论，大麻素改善抑郁和焦虑症的证据很薄弱，质量非常低，并且没有为在监管框架内使用大麻素治疗精神健康状况提供指导。迫切需要进行高质量的研究来检查大麻素对一般精神障碍，特别是抑郁/焦虑的影响，以及长期使用这些制剂由于可能的风险（如成瘾甚至改善逆转）而产生的后果。
Background: There is a growing liberalization of cannabis-based preparations for medical and recreational use. In multiple instances, anxiety and depression are cited as either a primary or a secondary reason for the use of cannabinoids. Aim: The purpose of this review is to explore the association between depression or anxiety and the dysregulation of the endogenous endocannabinoid system (ECS), as well as the use of phytocannabinoids and synthetic cannabinoids in the remediation of depression/anxiety symptoms. After a brief description of the constituents of cannabis, cannabinoid receptors and the endocannabinoid system, the most important evidence is presented for the involvement of cannabinoids in depression and anxiety both in human and from animal models of depression and anxiety. Finally, evidence is presented for the clinical use of cannabinoids to treat depression and anxiety. Conclusions: Although the common belief that cannabinoids, including cannabis, its main studied components—tetrahydrocannabinol (THC) and cannabidiol (CBD)—or other synthetic derivatives have been suggested to have a therapeutic role for certain mental health conditions, all recent systematic reviews that we report have concluded that the evidence that cannabinoids improve depressive and anxiety disorders is weak, of very-low-quality, and offers no guidance on the use of cannabinoids for mental health conditions within a regulatory framework. There is an urgent need for high-quality studies examining the effects of cannabinoids on mental disorders in general and depression/anxiety in particular, as well as the consequences of long-term use of these preparations due to possible risks such as addiction and even reversal of improvement.
登录
查看更多内容
影响因子：
4.7
作者：
Araque A;Castillo PE;Manzoni OJ;Tonini R
通讯作者：
Tonini R
影响因子：
4.7
作者：
Aso, Ester;Ozaita, Andres;Valverde, Olga
通讯作者：
Valverde, Olga
DOI：
10.1016/j.pnpbp.2012.02.006
发表时间：
2012-07-02
影响因子：
5.6
作者：
Bambico, Francis Rodriguez;Hattan, Patrick R.;Gobbi, Gabriella
通讯作者：
Gobbi, Gabriella
影响因子：
39.2
作者：
CHANG, AE;SHILING, DJ;ROSENBERG, SA
通讯作者：
ROSENBERG, SA
DOI：
10.1590/1516-4446-2021-1926
发表时间：
2022-01
期刊：
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
影响因子：
--
作者：
Ahmed M;Boileau I;Le Foll B;Carvalho AF;Kloiber S
通讯作者：
Kloiber S